Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McCall

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Plos One|September 2, 2009
Caspase-12 and the inflammatory response to Yersinia pestisBart Ferwerda, Matthew B B McCall, Maaike C de Vries, et al.
Science Translational Medicine|June 23, 2017
Infectivity of <i>Plasmodium falciparum</i> sporozoites determines emerging parasitemia in infected volunteersMatthew B B McCall, Linda J Wammes, Marijke C C Langenberg, et al.
Antimicrobial Resistance and Infection Control|December 30, 2025
Local translation of national guidance on discontinuing COVID-19 isolation into hospital policies results in considerable differencesCynthia P Haanappel, Juliëtte A Severin, Karin Ellen Veldkamp, et al.
Npj Drug Discovery|June 30, 2026
Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trialJonne Terstappen, Elisabeth E Nibbelke, Stephanie Ascough, et al.
Plos Neglected Tropical Diseases|May 21, 2024
Eosinophils, basophils and myeloid-derived suppressor cells in chronic Loa loa infection and its treatment in an endemic settingGerrit Burger, Rafiou Adamou, Ruth Kreuzmair, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adultsSaskia C van der Boor, Merel J Smit, Stijn W van Beek, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
NPJ Vaccines|April 15, 2025
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine developmentE Z Siegal, J M H Schoevers, J Terstappen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2007
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humansBart Ferwerda, Matthew B B McCall, Santos Alonso, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Plos One|September 2, 2009
Caspase-12 and the inflammatory response to Yersinia pestisBart Ferwerda, Matthew B B McCall, Maaike C de Vries, et al.
Science Translational Medicine|June 23, 2017
Infectivity of <i>Plasmodium falciparum</i> sporozoites determines emerging parasitemia in infected volunteersMatthew B B McCall, Linda J Wammes, Marijke C C Langenberg, et al.
Antimicrobial Resistance and Infection Control|December 30, 2025
Local translation of national guidance on discontinuing COVID-19 isolation into hospital policies results in considerable differencesCynthia P Haanappel, Juliëtte A Severin, Karin Ellen Veldkamp, et al.
Npj Drug Discovery|June 30, 2026
Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trialJonne Terstappen, Elisabeth E Nibbelke, Stephanie Ascough, et al.
Plos Neglected Tropical Diseases|May 21, 2024
Eosinophils, basophils and myeloid-derived suppressor cells in chronic Loa loa infection and its treatment in an endemic settingGerrit Burger, Rafiou Adamou, Ruth Kreuzmair, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adultsSaskia C van der Boor, Merel J Smit, Stijn W van Beek, et al.
The New England Journal of Medicine|November 20, 2024
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria ParasiteOlivia A C Lamers, Blandine M D Franke-Fayard, Jan Pieter R Koopman, et al.
The Lancet. Microbe|January 21, 2023
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2Merel J Smit, Adam F Sander, Maud B P A Ariaans, et al.
NPJ Vaccines|April 15, 2025
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine developmentE Z Siegal, J M H Schoevers, J Terstappen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2007
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humansBart Ferwerda, Matthew B B McCall, Santos Alonso, et al.
Pageof 25